[
  {
    "ts": null,
    "headline": "The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week",
    "summary": "23andMe said late Friday that TTAM Research Institute, Wojcicki’s nonprofit, was offering $305 million for the company’s assets.  Last month, 23andMe said that biotech firm  Regeneron  had won the bidding during a bankruptcy auction to buy the company for $256 million.  The bidding reopened after TTAM made its unsolicited offer.",
    "url": "https://finnhub.io/api/news?id=47cceaa2aa25d9280f150a857cce2ee35c863094e79de4510a6351b1e48b8acf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750452180,
      "headline": "The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week",
      "id": 135445819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "23andMe said late Friday that TTAM Research Institute, Wojcicki’s nonprofit, was offering $305 million for the company’s assets.  Last month, 23andMe said that biotech firm  Regeneron  had won the bidding during a bankruptcy auction to buy the company for $256 million.  The bidding reopened after TTAM made its unsolicited offer.",
      "url": "https://finnhub.io/api/news?id=47cceaa2aa25d9280f150a857cce2ee35c863094e79de4510a6351b1e48b8acf"
    }
  },
  {
    "ts": null,
    "headline": "Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says",
    "summary": "(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday.  About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite.  Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.",
    "url": "https://finnhub.io/api/news?id=31e04751efb01a7bf3c2e3b744bcab43803917e4596b88c0d81b6918a1f61ed6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750448742,
      "headline": "Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says",
      "id": 135443728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday.  About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly's Zepbound or Novo's Wegovy, both of which target the GLP-1 protein to help control appetite.  Investors are closely watching mid-stage data from Lilly's muscle mass-preserving drug, bimagrumab, which is scheduled for presentation at a medical conference next week.",
      "url": "https://finnhub.io/api/news?id=31e04751efb01a7bf3c2e3b744bcab43803917e4596b88c0d81b6918a1f61ed6"
    }
  },
  {
    "ts": null,
    "headline": "From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M",
    "summary": "Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute, the company announced on Friday. The deal marks the final stage in a bidding contest that began after 23andMe filed for Chapter 11 bankruptcy in March. According to the company, TTAM will acquire substantially all of 23andMe's assets, including its Personal Genome Service, Research Services, and Lemonaid Hea",
    "url": "https://finnhub.io/api/news?id=d6b6c2a1dd69cf1576319132466c068c1a9c055eadd4069b001a952b7bd0ca1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750437143,
      "headline": "From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M",
      "id": 135441076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute, the company announced on Friday. The deal marks the final stage in a bidding contest that began after 23andMe filed for Chapter 11 bankruptcy in March. According to the company, TTAM will acquire substantially all of 23andMe's assets, including its Personal Genome Service, Research Services, and Lemonaid Hea",
      "url": "https://finnhub.io/api/news?id=d6b6c2a1dd69cf1576319132466c068c1a9c055eadd4069b001a952b7bd0ca1e"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid",
    "summary": "SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.",
    "url": "https://finnhub.io/api/news?id=578585cbc876c86441177a3b7d3d25d163967e3c46a4eb0d7074114e229a2b34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750427160,
      "headline": "Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid",
      "id": 135441077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.",
      "url": "https://finnhub.io/api/news?id=578585cbc876c86441177a3b7d3d25d163967e3c46a4eb0d7074114e229a2b34"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)",
    "summary": "Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respira",
    "url": "https://finnhub.io/api/news?id=42552a315c5bd331ae5169be67fd4c2284eb07b7114b71972309e480fa476d45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750395600,
      "headline": "Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)",
      "id": 135441078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respira",
      "url": "https://finnhub.io/api/news?id=42552a315c5bd331ae5169be67fd4c2284eb07b7114b71972309e480fa476d45"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent for the Treatment of Adult Patients with Bullous Pemphigoid",
    "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult patients with bullous pemphigoid. These statements...",
    "url": "https://finnhub.io/api/news?id=177e3dfc15289a29c6b13c0dfb996c172bb12578e0b76ff388c018ed77f8eb3c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750385128,
      "headline": "Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent for the Treatment of Adult Patients with Bullous Pemphigoid",
      "id": 135416366,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult patients with bullous pemphigoid. These statements...",
      "url": "https://finnhub.io/api/news?id=177e3dfc15289a29c6b13c0dfb996c172bb12578e0b76ff388c018ed77f8eb3c"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi and Regeneron's Dupixent Approves in the US as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid",
    "summary": "Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid. Approval based on pivotal results showing improvements in sustained disease remission and...",
    "url": "https://finnhub.io/api/news?id=6b33d3d5209c38dc53c6484a8e62df0d0e3ef31a748445919b7bf271600085ef",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750385121,
      "headline": "Sanofi and Regeneron's Dupixent Approves in the US as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid",
      "id": 135416367,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid. Approval based on pivotal results showing improvements in sustained disease remission and...",
      "url": "https://finnhub.io/api/news?id=6b33d3d5209c38dc53c6484a8e62df0d0e3ef31a748445919b7bf271600085ef"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease",
    "summary": "Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease",
    "url": "https://finnhub.io/api/news?id=0f6e8884c4593580115fd796ee5d7cf98d0c79a376042ea9a753aa7955acac9f",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750384860,
      "headline": "Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease",
      "id": 135432270,
      "image": "",
      "related": "REGN",
      "source": "DowJones",
      "summary": "Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease",
      "url": "https://finnhub.io/api/news?id=0f6e8884c4593580115fd796ee5d7cf98d0c79a376042ea9a753aa7955acac9f"
    }
  }
]